In morning trade the Avita Therapeutics Inc (ASX: AVH) share price is pushing higher after the release of its first quarter update.
At the time of writing the regenerative medicine company’s shares are up 2% to $6.23.
How did Avita perform in the first quarter?
For the three months ended 30 September, Avita reported total global revenue of US$5.1 million. This was up 56% on the prior corresponding period.
This revenue is made up almost entirely of its U.S based RECELL revenue, which came in 59% higher than the same period last year at US$5 million.
This was driven by a 27.2% increase in procedural volumes to 496 and the addition of 9 new accounts in the first quarter. The latter brings its total accounts to 86.
Avita reported a gross margin of 82% for the first quarter of 2021, compared with 81% in the same quarter last year.
However, its operating expenses are still vastly greater than the money it is bringing in. Operating expenses were US$14.9 million for the first quarter, up from US$8.3 million for the prior corresponding period.
Management advised that this increase was primarily driven by the additional costs incurred from its dual listed entity on the NASDAQ and the ASX, along with the commencement of pivotal clinical trials for the treatment of paediatric scald injuries, soft tissue reconstruction, vitiligo and other research and development activities aiming to further promote the RECELL System.
In light of this, Avita posted a net loss of US$10.2 million for the quarter. This led to the company finishing the period with a cash balance of US$65.8 million.
Outlook.
Due to the uncertainty surrounding the COVID-19 pandemic, management advised that it will not be providing financial guidance at this time.
However, it will continue to evaluate its guidance policies and anticipates providing an update at the time of its second quarter earnings announcement based on available information at that time.
Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
Find out the names of our 3 Post COVID Stocks – For FREE!
*Returns as of 6/8/2020
More reading
- Why Alcidion, Avita, BHP, & REA Group shares are storming higher
- AVITA Therapeutics (ASX:AVH) share price climbs higher on reverse ageing project
- 3 ASX small cap shares you must add to your watchlist
- The ASX 200 sank almost 2% today
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Avita Medical Limited. The Motley Fool Australia has recommended Avita Medical Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post Avita Therapeutics (ASX:AVH) share price higher following Q1 update appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/38uGrL6
Leave a Reply